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Abstract
Recent technical advances have begun to realize the potential of molecular beacons to test for diverse
infections in clinical diagnostic laboratories. These include the ability to test for, and quantify, multiple
pathogens in the same clinical sample, and to detect antibiotic resistant strains within hours. The
design principles of molecular beacons have also spawned a variety of allied technologies.
Introduction
Imagine a magic reagent to which is added a droplet of
body fluid from a patient. A glow appears in the tube and
the color of the glow identifies the pathogen responsible
forthepatient‘sillness.Suchwasthepromiseofmolecular
beacons when they were first introduced 15 years ago [1].
That promise is now bearing fruit, as powerful new tests
for diverse infections are being introduced into clinical
diagnostic laboratories.
Molecular beacons are hairpin-shaped oligonucleotide
probes that become fluorescent upon hybridization to
an RNA or DNA target sequence. Their loops serve as
probes and are about 15 to 25 nucleotides long. Their
stems serve to bring the two ends of the molecule,
which are linked to a fluorophore and a quencher, into
close proximity. Although the stems are only 5 to 7
nucleotides long, they keep the labels in close proximity
so that the fluorescence of the fluorophore is quenched
in the free probes. However, upon binding to their
target, they undergo a spontaneous conformational
reorganization that removes the fluorophore from the
vicinity of the quencher and restores its fluorescence
(Figure 1). Molecular beacons specific for different
target sequences and labeled with differently colored
fluorophores can be used together to simultaneously
identify and quantitate multiple targets in the same
assay tube [2].
Given this fluorogenic response, the addition ofthe probes
tonucleicacidsisolatedfromaclinicalsamplecontaininga
relatively large number of infectious agents would be
sufficient to generate a detectable signal. However, human
clinical samples contain only miniscule amounts of
pathogen-derived nucleic acids. It is therefore necessary
to first amplify an identifying target sequence from the
pathogen‘s nucleic acid. In a typical assay, nucleic acids are
extractedfromthesample,andasegmentofthepathogen‘s
genome (containing the target sequence) is amplified in a
polymerase chain reaction (PCR), or in a nucleic acid
sequence-based amplification (NASBA) reaction, while
simultaneously monitoring the fluorescence of the target-
specific molecular beacons in the reaction mixture [1-3].
Since fluorescence is measured in sealed tubes, carryover
contamination, which plagued earlierassays, cannot occur.
Moreover, the measurement of fluorescence is in real time,
as opposed to making measurements at end points, which
enables quantitation over an extremely wide dynamic
r a n g eo ft a r g e tc o n c e n t r a t i o n s[ 4 ] .
Recent advances
Soon after the introduction of molecular beacons and
other target-specific fluorogenic probes, such as TaqMan
probes [1,5], spectrofluorometric thermal cyclers became
available that could perform PCR assays while simulta-
neously monitoring fluorescence changes. In addition,
automated nucleic acid extraction protocols were
Page 1 of 6
(page number not for citation purposes)
Published: 02 May 2012
© 2012 Faculty of 1000 Ltdintroduced. With the availability of these resources, the
development of nucleic acid-based assays for pathogens
became relatively simple, and there are now a large
number of tests available for the detection of human
pathogens, and food and environmental contaminants
(Table 1).
Mostoftheassayslistedinthetablearedesignedtodetect
an individual pathogenic species. However, it is often
desirable to determine the type of pathogens that are
presentin a clinical sample, for example,does the sample
contain Gram-negative bacteria, Gram-positive bacteria,
or a fungal species [6]? These tests would be even more
powerful if they could determine which species (from a
selected list) is present, and indeed, investigators have
recently developed tests that do this. For example, in a
singleassay,Chakravorty and his colleagues [7] were able
to identify which pathogenic or commensal bacterial
species was present in a blood sample from a list of 111
species in 64 different genera. Similarly, El-Hajj and her
colleagues [8] have developed an assay that distinguishes
27 different species of Mycobacteria. These assays include
several molecular beacons labeled with differently
colored fluorophores in the same tube. Current instru-
ments are able to distinguish up to seven fluorescent
colors in the same tube, which suggests a limit of seven
targets. So, to achieve this high level of multiplexing, the
assays not only distinguish the fluorescence of each
differently colored molecular beacon, they measure the
characteristic stability of the probe-target hybrids that
each molecular beacon forms by raising the temperature
to see when each molecular beacon dissociates from the
target (causing a marked decrease in fluorescence). This
analysis identifies the target by indicating the relation-
ship of the probe sequence to the target sequence. If the
probe is a good match to the target, the probe-target
hybrid is quite stable, and this stability is reflected in a
high melting temperature, whereas, if the probe is not a
good match to the target, the probe-target hybrid is less
stable and melts apart at a lower temperature.
Some ofthese testscan also determinewhether the specific
pathogen has acquired drug resistance. For example, an
assay developed by Alland and colleagues [9-11] for
Mycobacterium tuberculosis detects the bacterial RNA poly-
merase gene with several different molecular beacons that
are so specific that the presence of any mutation in the
targetregioncausesoneofthedifferentlycoloredmolecular
beacons not to bind to the target (indicating that the
commonly used antibiotic rifampicin will not be able to
inhibit the activity of the encoded RNA polymerase). This
PCR assay takes only two hours, whereas traditional
culture-based tests take at least two weeks.
In a number of clinical situations, it is necessary to detect
hundreds or thousands of targets at the same time. For
example, such situations occur when the mutations
responsible for drug resistance are scattered over long
sequence stretches, or can be present on multiple genes.
To probe for a large number of mutations, new assay
formats are under development that simultaneously
screen genomes with thousands of molecular beacons. In
these formats, different molecular beacons are immobi-
lized at different locations of a planner array [12], on the
surface of beads trapped in microfluidic chambers [13],
or on different locations of nanowires [14]. The locations
that become fluorescent indicate which mutations are
present.
It is not always necessary to amplify nucleic acid to detect
a pathogen. Molecular beacons complementary to
species-specific regions of ribosomal RNA can be used
to identify bacterial and fungal pathogens by in situ
hybridization. Innovel“molecularblood culture”assays,
pathogens are grown for a short period and then
Figure 1. Principle of operation of molecular beacons
In the free probes, a fluorophore attached at one of the molecule (red ball)
is held close to a quencher (black ball) attached at the other end of the
molecule, so that the probe is not fluorescent. The interaction of the
sequence in the loop with the target separates the fluorophore and
quencher and causes the fluorophore to become fluorescent.
Page 2 of 6
(page number not for citation purposes)
F1000 Medicine Reports 2012, 4:10 http://f1000.com/reports/m/4/10identified by in situ hybridization with molecular
beacons, followed by imaging [15].
In addition to their main attribute (that they generate
signals without having to separate probe target-hybrids
from excess probes, thereby enabling sealed-tube assays),
molecular beacons also introduced several design prin-
ciples that have inspired the development of other kinds
of probes. Among these are the use of non-fluorescent
dyes as quenchers of fluorescence, the use of hairpins as a
means of keeping fluorophores in close contact with
quenchers, and the use of hairpins to increase the specifi-
city of hybridization. A small industry of non-fluorescent
quenchers, often called “dark” quenchers, with names
such as Eclipse, Iowa Black, BlackBerry, and Black Hole
Quenchers has been spawned [16]. Dark quenchers
afford a larger extent of multiplexing, since they do not
crowdtheavailablespectrumbyemittinglight.Anumber
of novel probe formats that utilize hairpins as their
central element have also been introduced. For example,
Amplifluor Primers contain a 5‘ hairpin that possesses a
fluorophore and a quencher in close contact, but once the
resulting amplicon (a piece of DNA that has been
synthesized using amplification techniques) is copied,
the fluorophore and quencher are separated, generating
a bright fluorescence signal [17]. In another variant, called
Scorpion Primers, a molecular beacon is attached at the 5‘
end of the primer, but in this case, it cannot be copied.
However, the molecular beacon is designed to bind to a
segment of the amplified DNA. Since the probe and the
target are now in the same molecule, the molecular beacon
can come around and bind to the target. This intramole-
cular interaction happens more readily than the inter-
molecular binding of a normal molecular beacon [18].
Future directions
Recent years have seen a wave of technical advances that
have begun to realize the potential of molecular beacons
to test for diverse human pathogens in clinical diagnostic
laboratories, and also food and environmental contami-
nants. These include new techniques with the ability to
test for, and quantify, multiple pathogens in the same
Table 1. Molecular beacon-based assays for pathogens
Organism Amplification Scheme References
Human Pathogens
HIV NASBA, PCR [4,19,20]
HTLV PCR [4,21]
Oncogenic HPV NASBA, PCR [22-24]
Mycobacterium tuberculosis PCR [9-11,25]
hMPV NASBA [26]
RSV NASBA, PCR [27-29]
Enterovirus NASBA [30,31]
Influenza virus NASBA, PCR [32,33]
Entamoeba histolytica PCR [34]
Methicillin-resistant Staphylococcus PCR [35-37]
Hepatitis B NASBA, PCR [38,39]
HPIV NASBA [40]
West Nile virus NASBA, PCR [41,42]
Candida dubliniensis PCR [43]
Scedosporium PCR [44]
Pan-bacteria NASBA, PCR, melting analysis [6,7]
Pan-fungi NASBA, PCR [6]
27 Mycobacterial species PCR, melting analysis [8]
6 Pneumonia-causing agents PCR [45]
Chlamydophila pneumoniae NASBA [46]
Multiple bacteria in blood stream PCR [47]
Lyme disease spirochetes PCR [48]
Plasmodium NASBA, PCR [49,50]
Food Pathogens
Salmonella PCR [51]
Escherichia coli NASBA [52]
Listeria NASBA [53]
8 food pathogens PCR, melting analysis [54]
Environmental Pathogens
Salmonella PCR [55]
Escherichia coli PCR [56]
Baylisascaris procyonis PCR [57]
Vibrio cholerae NASBA, PCR [58,59]
Bacillus anthracis PCR [60]
Abbreviations: hMPV, human metapneumovirus; HPIV, human parainfluenza virus; RSV, respiratory syncytial virus.
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within hours.
As molecular beacons and allied technologies are
adopted in the clinical diagnostics industry, physicians
will be able to diagnose diseases with greater precision
than ever before.
Abbreviations
NASBA, nucleic acid sequence-based amplification; PCR,
polymerase chain reaction.
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